Explore the vast range of titles available.

Although historically materials discovery has been driven by a laborious trial-and-error process, knowledge-driven materials design can now be enabled by the rational combination of Machine Learning methods and materials databases. Here, data from the AFLOW repository for ab initio calculations is combined with Quantitative Materials Structure-Property Relationship models to predict important properties: metal/insulator classification, band gap energy, bulk/shear moduli, Debye temperature and heat capacities. The prediction’s accuracy compares well with the quality of the training data for virtually any stoichiometric inorganic crystalline material, reciprocating the available thermomechanical experimental data. The universality of the approach is attributed to the construction of the descriptors: Property-Labelled Materials Fragments. The representations require only minimal structural input allowing straightforward implementations of simple heuristic design rules. Machine learning methods can be useful for materials discovery; however certain properties remain difficult to predict. Here, the authors present a universal machine learning approach for modelling the properties of inorganic crystals, which is validated for eight electronic and thermomechanical properties.

Quantitative Structure Activity Relationship (QSAR) modeling has been traditionally applied as an evaluative approach, i.e., with the focus on developing retrospective and explanatory models of existing data. Model extrapolation was considered if only in hypothetical sense in terms of potential modifications of known biologically active chemicals that could improve compounds activity. This critical review re-examines the strategy and the output of the modern QSAR modeling approaches. We provide examples and arguments suggesting that current methodologies may afford robust and validated models capable of accurate prediction of compound properties for molecules not included in the training sets. We discuss a data-analytical modeling workflow developed in our laboratory that incorporates modules for combinatorial QSAR model development (i.e., using all possible binary combinations of available descriptor sets and statistical data modeling techniques), rigorous model validation, and virtual screening of available chemical databases to identify novel biologically active compounds. Our approach places particular emphasis on model validation as well as the need to define model applicability domains in the chemistry space. We present examples of studies where the application of rigorously validated QSAR models to virtual screening identified computational hits that were confirmed by subsequent experimental investigations. The emerging focus of QSAR modeling on target property forecasting brings it forward as predictive, as opposed to evaluative, modeling approach.

Deep learning has disrupted nearly every field of research, including those of direct importance to drug discovery, such as medicinal chemistry and pharmacology. This revolution has largely been attributed to the unprecedented advances in highly parallelizable graphics processing units (GPUs) and the development of GPU-enabled algorithms. In this Review, we present a comprehensive overview of historical trends and recent advances in GPU algorithms and discuss their immediate impact on the discovery of new drugs and drug targets. We also cover the state-of-the-art of deep learning architectures that have found practical applications in both early drug discovery and consequent hit-to-lead optimization stages, including the acceleration of molecular docking, the evaluation of off-target effects and the prediction of pharmacological properties. We conclude by discussing the impacts of GPU acceleration and deep learning models on the global democratization of the field of drug discovery that may lead to efficient exploration of the ever-expanding chemical universe to accelerate the discovery of novel medicines. GPUs, which are highly parallel computer processing units, were originally designed for graphics applications, but they have played an important role in accelerating the development of deep learning methods. In this Review, Pandey and colleagues summarize how GPUs have advanced machine learning in the field of drug discovery.

Myocarditis and pericarditis have been linked recently to COVID-19 vaccines without exploring the underlying mechanisms, or compared to cardiac adverse events post-non-COVID-19 vaccines. We introduce an informatics approach to study post-vaccine adverse events on the systems biology level to aid the prioritization of effective preventive measures and mechanism-based pharmacotherapy by integrating the analysis of adverse event reports from the Vaccine Adverse Event Reporting System (VAERS) with systems biology methods. Our results indicated that post-vaccine myocarditis and pericarditis were associated most frequently with mRNA COVID-19 vaccines followed by live or live-attenuated non-COVID-19 vaccines such as smallpox and anthrax vaccines. The frequencies of cardiac adverse events were affected by vaccine, vaccine type, vaccine dose, sex, and age of the vaccinated individuals. Systems biology results suggested a central role of interferon-gamma (INF-gamma) in the biological processes leading to cardiac adverse events, by impacting MAPK and JAK-STAT signaling pathways. We suggest that increasing the time interval between vaccine doses minimizes the risks of developing inflammatory adverse reactions. We also propose glucocorticoids as preferred treatments based on system biology evidence. Our informatics workflow provides an invaluable tool to study post-vaccine adverse events on the systems biology level to suggest effective mechanism-based pharmacotherapy and/or suitable preventive measures.

Deep generative neural networks have been used increasingly in computational chemistry for de novo design of molecules with desired properties. Many deep learning approaches employ reinforcement learning for optimizing the target properties of the generated molecules. However, the success of this approach is often hampered by the problem of sparse rewards as the majority of the generated molecules are expectedly predicted as inactives. We propose several technical innovations to address this problem and improve the balance between exploration and exploitation modes in reinforcement learning. In a proof-of-concept study, we demonstrate the application of the deep generative recurrent neural network architecture enhanced by several proposed technical tricks to design inhibitors of the epidermal growth factor (EGFR) and further experimentally validate their potency. The proposed technical solutions are expected to substantially improve the success rate of finding novel bioactive compounds for specific biological targets using generative and reinforcement learning approaches. Deep generative neural networks are increasingly exploited for drug discovery, but often the majority of generated molecules are predicted to be inactive. Here, an optimized protocol for generative models with reinforcement learning is derived and applied to design potent epidermal growth factor inhibitors.

The Structural Genomics Consortium is an international open science research organization with a focus on accelerating early-stage drug discovery, namely hit discovery and optimization. We, as many others, believe that artificial intelligence (AI) is poised to be a main accelerator in the field. The question is then how to best benefit from recent advances in AI and how to generate, format and disseminate data to enable future breakthroughs in AI-guided drug discovery. We present here the recommendations of a working group composed of experts from both the public and private sectors. Robust data management requires precise ontologies and standardized vocabulary while a centralized database architecture across laboratories facilitates data integration into high-value datasets. Lab automation and opening electronic lab notebooks to data mining push the boundaries of data sharing and data modeling. Important considerations for building robust machine-learning models include transparent and reproducible data processing, choosing the most relevant data representation, defining the right training and test sets, and estimating prediction uncertainty. Beyond data-sharing, cloud-based computing can be harnessed to build and disseminate machine-learning models. Important vectors of acceleration for hit and chemical probe discovery will be (1) the real-time integration of experimental data generation and modeling workflows within design-make-test-analyze (DMTA) cycles openly, and at scale and (2) the adoption of a mindset where data scientists and experimentalists work as a unified team, and where data science is incorporated into the experimental design. Artificial intelligence is greatly accelerating research in drug discovery, but its development is still hindered by the lack of available data. Here the authors present data management and data science recommendations to help reach AI’s potential in the field.

Purpose Development of externally predictive Quantitative Structure–Activity Relationship (QSAR) models for Blood–Brain Barrier (BBB) permeability. Methods Combinatorial QSAR analysis was carried out for a set of 159 compounds with known BBB permeability data. All six possible combinations of three collections of descriptors derived from two-dimensional representations of molecules as chemical graphs and two QSAR methodologies have been explored. Descriptors were calculated by MolconnZ, MOE, and Dragon software. QSAR methodologies included k -Nearest Neighbors and Support Vector Machine approaches. All models have been rigorously validated using both internal and external validation methods. Results The consensus prediction for the external evaluation set afforded high predictive power ( R 2  = 0.80 for 10 compounds within the applicability domain after excluding one activity outlier). Classification accuracies for two additional external datasets, including 99 drugs and 267 organic compounds, classified as permeable (BBB+) or non-permeable (BBB−) were 82.5% and 59.0%, respectively. The use of a fairly conservative model applicability domain increased the prediction accuracy to 100% and 83%, respectively (while naturally reducing the dataset coverage to 60% and 43%, respectively). Important descriptors that affect BBB permeability are discussed. Conclusion Models developed in these studies can be used to estimate the BBB permeability of drug candidates at early stages of drug development.

Pancreatic cancer treatment often relies on multi-drug regimens, but optimal combinations remain elusive. This study evaluates predictive approaches to identify synergistic drug combinations using a dataset from the National Center for Advancing Translational Sciences (NCATS). Screening 496 combinations of 32 anticancer compounds against the PANC-1 cells experimentally determined the degree of synergism and antagonism. Three research groups (NCATS, University of North Carolina, and Massachusetts Institute of Technology) leverage these data to apply machine learning (ML) approaches, predicting synergy across 1.6 million combinations. Of the 88 tested, 51 show synergy, with graph convolutional networks achieving the best hit rate and random forest the highest precision. Beyond highlighting the potential of ML, this work delivers 307 experimentally validated synergistic combinations, demonstrating its practical impact in treating pancreatic cancer. Finding optimal multi-drug combinations for pancreatic cancer remains a complex task. Here, authors across three different groups apply machine learning approaches to predict synergy across 1.6 million combinations of drugs for pancreatic cancer, 307 of which are validated experimentally.

COVID-19 vaccines have been instrumental tools in reducing the impact of SARS-CoV-2 infections around the world by preventing 80% to 90% of hospitalizations and deaths from reinfection, in addition to preventing 40% to 65% of symptomatic illnesses. However, the simultaneous large-scale vaccination of the global population will indubitably unveil heterogeneity in immune responses as well as in the propensity to developing post-vaccine adverse events, especially in vulnerable individuals. Herein, we applied a systems biology workflow, integrating vaccine transcriptional signatures with chemogenomics, to study the pharmacological effects of mRNA vaccines. First, we derived transcriptional signatures and predicted their biological effects using pathway enrichment and network approaches. Second, we queried the Connectivity Map (CMap) to prioritize adverse events hypotheses. Finally, we accepted higher-confidence hypotheses that have been predicted by independent approaches. Our results reveal that the mRNA-based BNT162b2 vaccine affects immune response pathways related to interferon and cytokine signaling, which should lead to vaccine success, but may also result in some adverse events. Our results emphasize the effects of BNT162b2 on calcium homeostasis, which could be contributing to some frequently encountered adverse events related to mRNA vaccines. Notably, cardiac side effects were signaled in the CMap query results. In summary, our approach has identified mechanisms underlying both the expected protective effects of vaccination as well as possible post-vaccine adverse effects. Our study illustrates the power of systems biology approaches in improving our understanding of the comprehensive biological response to vaccination against COVID-19.

Traditional best practices for quantitative structure activity relationship (QSAR) modeling recommend dataset balancing and balanced accuracy (BA) as the key desired objective of model development. This study explores the value of the conventional norms in the context of using QSAR models for virtual screening of modern large and ultra-large chemical libraries. For this increasingly common task, we now recommend the use of models with the highest positive predictive value (PPV) built on imbalanced training sets as preferred virtual screening tools. This recommendation stems from practical considerations of how the results of virtual screening are used in experimental laboratories where only a small fraction of virtually screened molecules can be tested using standard well plates. As a proof of concept, we have developed QSAR models for five expansive datasets with different ratios of active and inactive molecules and compared model performance in virtual screening using BA, PPV, and other metrics. We show that training on imbalanced datasets achieves a hit rate at least 30% higher than using balanced datasets, and that the PPV metric captured this difference of performance with no parameter tuning. Importantly, hit rates were estimated for top scoring compounds organized in batches of the size of plates (for instance, 128 molecules) used in the experimental high throughput screening. Based on the results of our studies, we posit that QSAR models trained on imbalanced datasets with the highest PPV should be relied upon to identify and test hit compounds in early drug discovery studies.